ORYZON anuncia datos clínicos positivos de iadademstat en el congreso ASH-2025
Los datos preliminares del ensayo de Fase Ib en curso de iadademstat en combinación con azacitidina y venetoclax en pacientes
Leer másLos datos preliminares del ensayo de Fase Ib en curso de iadademstat en combinación con azacitidina y venetoclax en pacientes
Leer másPatente europea refuerza la protección de iadademstat en combinación con inhibidores PD1/PD-L1 para terapias contra el cáncer hasta 2040 Oryzon
Leer másPrimer ensayo clínico de iadademstat en una indicación hematológica no maligna Oryzon Genomics S.A., compañía biofarmacéutica de fase clínica y
Leer más| Cookie | Duración | Descripción |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |